Irreversible FGFR1–4 Inhibitor Futibatinib in Patients With Unresectable/Metastatic Tumors: Safety Profile and Adverse Event Management
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety Profile and Adverse Event Management for Futibatinib, an Irreversible FGFR1-4 Inhibitor: Pooled Safety analysis of 469 patients
Clin. Cancer Res 2024 Feb 08;[EPub Ahead of Print], F Meric-Bernstam, A Hollebecque, J Furuse, DY Oh, JA Bridgewater, M Shimura, B Anderson, N Hangai, V Wacheck, L GoyalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.